News

Based in Athens of Greece, Genepharm is involved in the development, manufacturing and out-licensing of high-value generic pharmaceutical products. The company, which owns a wide portfolio of products,

Under the three-year deal, the partnership will use insitro’s platform to create disease models for NASH and discover targets that can impact clinical progression and regression of the

iPSCs can be derived from adult human tissue cells yet share the developmental potentials of embryonic stem cells. Currently Japan has 6 ongoing clinical trials utilizing this technology,

The study will enroll approximately eight patients with PH1 under six years of age. The primary endpoint is the percent reduction in urinary oxalate from baseline to six

Paragon Bioservices is a major viral vector development and manufacturing partner for gene therapies. Paragon president and CEO Pete Buzy said: “We are excited to join forces with

The company said that it used a priority review voucher to fast track the review of the regulator on brolucizumab in order to make it available to patients

The portfolio includes more than 30 generic injectable products. These products will require to be technology transferred and could be launched within the next one to two years.

The intended clinical trial will be a proof-of-concept study combining Novo Nordisk’s semaglutide (GLP-1 analogue) and Gilead’s cilofexor (FXR agonist) and firsocostat (ACC inhibitor) for the treatment of

Balversa is now indicated in the US for the treatment of adult patients having locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration